INCA035784 (novel investigational agent for MPN)

Current understanding

To be populated as evidence accumulates.

June 12-15 — Advancing Frontiers in Myeloproliferative Neoplasms - EHA 2025 Congress Review: EHA 2025 congress review (review-level) introduces INCA035784 as a novel T cell-redirecting antibody targeting mutant CALR, representing the first bispecific/T-cell-engager approach to the CALR neoepitope in MPN. (novelty: 3)
2026-04-06 — A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms: Phase 1/early-phase clinical trial launched to evaluate safety and tolerability of INCA035784 in MPN patients (trial-early; mechanism/class not disclosed in available abstract). (novelty: 4)